canada clinical guidance

Asthma

A Canadian clinical summary of asthma, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by 2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CTS asthma 2021

Source-attributed clinical priorities

  • Confirm variable expiratory airflow limitation with objective testing whenever feasible; do not diagnose asthma from symptoms alone.
  • Use an inhaled-corticosteroid-containing strategy rather than short-acting bronchodilator monotherapy for ongoing asthma care.
  • Before stepping up, reassess diagnosis, inhaler technique, adherence, exposures, comorbidity and exacerbation risk.
  • Give every patient self-management education and a written action plan.
sources for this section:CTS asthma 2021

Practical assessment and management workflow

1
Record daytime and night symptoms, reliever use, activity limitation, lung function and exacerbations.
2
Verify spirometric variability or another accepted objective demonstration when the patient is stable.
3
Select an inhaled-corticosteroid-containing step from the CTS age and risk pathway.
4
Recheck control, exacerbation risk, technique and adherence before stepping up or down.
sources for this section:CTS asthma 2021

Safety, red flags and urgent escalation

  • Treat marked breathlessness, hypoxemia, exhaustion or a silent chest as an acute severe attack.
  • Do not let a normal examination between episodes override objective diagnostic testing.
  • Review oral-corticosteroid exposure and refer recurrent exacerbations or persistently uncontrolled disease.
sources for this section:CTS asthma 2021

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CTS asthma 2021

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CTS asthma 2021

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Thoracic Society2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adultsaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.